2021
Effect of age on brain metabotropic glutamate receptor subtype 5 measured with [18F]FPEB PET
Mecca AP, Rogers K, Jacobs Z, McDonald JW, Michalak HR, DellaGioia N, Zhao W, Hillmer AT, Nabulsi N, Lim K, Ropchan J, Huang Y, Matuskey D, Esterlis I, Carson RE, van Dyck CH. Effect of age on brain metabotropic glutamate receptor subtype 5 measured with [18F]FPEB PET. NeuroImage 2021, 238: 118217. PMID: 34052464, PMCID: PMC8378132, DOI: 10.1016/j.neuroimage.2021.118217.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAgingBrain ChemistryFemaleFluorine RadioisotopesFluorodeoxyglucose F18Gray MatterHippocampusHumansMagnetic Resonance ImagingMaleMiddle AgedNeuroimagingOrgan SizePositron-Emission TomographyRadiopharmaceuticalsReceptor, Metabotropic Glutamate 5Young AdultConceptsMetabotropic glutamate receptor subtype 5MGluR5 availabilityMultiple brain regionsTissue lossSubtype 5Association cortexPrimary analysisBrain regionsAge-related molecular changesBrain glutamatergic systemBrain tissue lossNon-significant trendPartial volume correctionPositron emission tomographyBrain mGluR5Effect of ageAge-related declineGlutamatergic systemInverse associationTissue alterationsDistribution volumeEmission tomographyOlder ageCognitive functionExploratory analysis
2020
PET imaging of mGluR5 in Alzheimer’s disease
Mecca AP, McDonald JW, Michalak HR, Godek TA, Harris JE, Pugh EA, Kemp EC, Chen MK, Salardini A, Nabulsi NB, Lim K, Huang Y, Carson RE, Strittmatter SM, van Dyck CH. PET imaging of mGluR5 in Alzheimer’s disease. Alzheimer's Research & Therapy 2020, 12: 15. PMID: 31954399, PMCID: PMC6969979, DOI: 10.1186/s13195-020-0582-0.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAlzheimer DiseaseBrainCognitive DysfunctionFemaleHumansMaleMiddle AgedPositron-Emission TomographyRadiopharmaceuticalsReceptor, Metabotropic Glutamate 5ConceptsEarly Alzheimer's diseaseAlzheimer's diseaseMild cognitive impairmentBrain amyloidHippocampus of ADPositron emission tomography radioligandSubtype 5 receptorsMild AD dementiaGray matter atrophyAssociation cortical regionsAmnestic mild cognitive impairmentImportant therapeutic targetCerebellum reference regionDynamic PET scansHippocampal mGluR5MethodsSixteen individualsMGluR5 bindingSynaptotoxic actionAD dementiaAD pathogenesisMatter atrophyInitial administrationAD groupSynaptic transmissionEntorhinal cortex
2019
1ciii AD molecular: Molecular imaging of Alzheimer's disease: PET imaging of neurotransmitter systems
Mecca AP. 1ciii AD molecular: Molecular imaging of Alzheimer's disease: PET imaging of neurotransmitter systems. Progress In Nucleic Acid Research And Molecular Biology 2019, 165: 139-165. PMID: 31481161, DOI: 10.1016/bs.pmbts.2019.04.003.Peer-Reviewed Original ResearchMeSH KeywordsAlzheimer DiseaseHumansMolecular ImagingNeurotransmitter AgentsPositron-Emission TomographyReceptor, Metabotropic Glutamate 5SynapsesConceptsMagnetic resonance imagingDisease pathogenesisSynaptic protein changesAlzheimer's disease (AD) pathogenesisEmission Tomography ImagingPositron emission tomography (PET) imagingNeurotransmitter lossMolecular imagingNeuropsychiatric symptomsImportant etiologyAssessment of cognitionDisease progressionNeurotransmitter systemsAmyloid βTherapeutic efficacyAlzheimer's diseaseResonance imagingSynaptic proteinsTau aggregatesValuable markerStudy of ADVivo molecular imagingTomography imagingPET imagingDisease